http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102173673-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6884 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5073 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2019-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102173673-B1 |
| titleOfInvention | Method for screening substances for the prevention or treatment of bronchopulmonary dysplasia (BPD) |
| abstract | The present invention relates to a method for screening a therapeutic agent for lung damage caused by administration of high oxygen concentration, and more specifically, screening a candidate substance for treating bronchopulmonary dysplasia (BPD) induced by administration of high oxygen to inhibit the expression or activity level of FPR1 It's about how. The present inventors discovered that FPR1 is overexpressed in lung tissue exposed to high concentrations of oxygen, and focused on the association between the expression of FPR1 and the onset of bronchopulmonary dysplasia, and found that if the expression or activity of FPR1 is inhibited, bronchopulmonary dysplasia can be suppressed. From the above facts, it is possible to quickly and accurately discover substances for preventing or treating bronchopulmonary dysplasia by checking whether the expression or activity level of FPR1 is suppressed, so it is usefully used to effectively screen and develop a therapeutic agent for bronchopulmonary dysplasia. Can be. |
| priorityDate | 2018-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 536.